Cardiorenal actions of the novel direct soluble guanylate cyclase stimulator BAY 41–2272 in experimental congestive heart failure in comparison to nitroglycerin  by Boerrigter, Guido et al.
JACC March 19,2003 ABSTRACTS - Vascular Disease, Hypertension, and Prevention 253A 
1081-153 Detection of Peripheral Arterial Disease in Patients 
Presenting for Coronary Angiography and/or 
Intervention Patients Study (PIPS) 
Issam Moussa, Roxana Mehran, Gary S. Roubin, Sriram lye,, Thosaphol Limpijankit. 
Monica Losquadro. Lynne Glasser, Heather Klein, Steven Slack, Martin B. Leon, Jeffrey 
W. Moses, Cardiovascular Research Foundation. New York, NY, Lenox Hill Hospital, 
New York, NY 
Background: The Partners Program has defined the prevalence of peripheral arterial 
disease (PAD) in an elderly communrty-dwelling population. The prevalence of PAD in 
high cardiovascular risk population undergoing coronary angiography for suspected cor- 
onary artery disease (CAD) is not known. 
Methods: PIPS is a prospective, single center study aimed to determine the prevalence 
of undiagnosed PAD in 800 consecutive patcents presenting for coronary angiography for 
suspected CAD. Enrolled pts underwent clinical assessment, an Ankle Brachial Index 
(ABI) measurement and completed the San Diego Questionaire. and the “PARTNERS 
quality of life questionnaire. A diagnosis of PAD was based on an ABldO.9. 
Results: As of September 6, 2002, 99 patients have been enrolled. Complete data was 
available for 68 patients(mean age =66&plusmnl5 years, 69% male). Diabetes and prior 
Ml were present in 26% and 41% of pts respectively. Angina pectoris was present in 73% 
of pts while only 6% reported intermittent claudicatlon. The prevalence of PAD in the 
overall population was 26%. Prevalence of PAD according to diabetes and smoking sta- 
tus is shown in the table. 
Conclusion: PAD is relatively common in patients with suspected CAD, especially in dia- 
betics (42%). These preliminary data suggest that implementation of systematic non- 
invasive screening program for PAD in selected pts referred for coronary angiography for 
detection of PAD. Complete data on 600 pts will be available at the time of presentation. 
DM (rk25) No DM (nz63) P-Value 
PAD 42% 21% 0.047 
Active or Former Smoker (n=50) Non-Smoker (n=38) 
PAD 25% 29% “S 
1081-154 Characterizing the Young Patient With Aortic 
Dissection: Results From the International Registry of 
Aortic Dissection (IRAD) 
James L. Januzzi, Eric M. Isselbacher, Rosella Fatton, Jeanna V. Cooper, Dean E. 
Smith. Kim A. Eaale. GhristoDh A. Nienaber. Linda A. Parx? for the International Reaistrv _ 
of Aortic DissectIon, Massachusetts General Hospital, Boston, MA, University of 
Massachusetts, Worcester, MA 
Backgound: Aortic dissection (AoD) is unusual in young patients. We wished to better 
characterize the young patient with AoD. Methods: From an international registry, data 
were collected on 1076 patients diagnosed with acute AoD between 1196 and 11101. 
Patients were divided into age categories of ~40 years and 40 years and older. Unlvari- 
ate analyses comparing groups were done using Chi-squared cross tabulations for cate- 
gorical data and the Student’s t-test for continuous data. Results: 69 patients (6.4%) with 
AoD ~40 years rn age were identified. The incidence of Type A dissection among 
patients ~40 was similar to patients 40 years and older (Table 1). Compared to patients 
40 years or older in age, younger AoD patients were less likely to have a prior history of 
tradibonal AoD risk factors such as hyparienslon (HTN), or atherosclerosis, but were 
more likely to have a hlstory of Marfan syndrome, bicuspid aortic valve (BAV), or prior 
aortic surgery (see table). ClinIcal presentabons and outcomes of patients were similar 
between the two age groups, although younger patients were less likely to present with 
hypertension (28.6% vs 47.1%, p=O.O04). Relative to older patients. the sizes of the 
proximal aorta of young AoD patients were routinely significantly larger (see table). An 
analysis of patients ~40 years of age suggests that these differences in aorlic size are 
not explained by Marfan syndrome. Conclusions: Compared to older patients with AoD, 
young patients wrth AoD have unique risk factors for dissection. 
Characteristic 
Type A dissection 
History of HTN 
Atherosclerosis 
Marfan syndrome 
BAV 
AVR 
Aortic annulus (cm) 
A&C root (cm) 
Sinotubularlunction (cm) 
Ascending aorta (cm) 
Table I 
Age less than 40 
68% 
35% 
2% 
49% 
16% 
13% 
3.4*1 .o 
4.9il.7 
4.6il.6 
5.3il.6 
Age 40 and older 
62% 
74% 
33% 
2% 
3% 
5% 
3.0r0.9 
4.1*1.0 
3.9*1 .o 
4.8*1.3 
P value 
NS 
<O.OOl 
<0.001 
<0.001 
0.001 
0.01 
0.04 
0.01 
0.05 
0.03 
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1082- 146 Conditional-Dependent Effects of CVT-4325, a Novel 
Fatty Acid Oxidation Inhibitor, on Palmitate Utilization 
Heather Frasec Jeffrey J. McVeigh, Prabha N. Ibrahim, Brent K. Blackburn. Luiz 
Belardinelli, CV Therapeutics, Inc., Palo Alto, CA 
Under aerobic conditions. the heart derives more ATP from the oxidation of fatty acids 
than glucose. However, fatty acid oxidation (FOX) is less efficient than glucose oxidation 
(GOX), in that more 02 is used to oxidize fatty acids than glucose to generate an equiva- 
lent amount of ATP. Hence, agents that decrease FOX and indirectly increase GOX 
(metabolic shift) may be useful therapeutic agents to enhance cardiac efficiency in condi- 
tions of myccardial 02 deficiency. CVT-4325, a novel piperazine derivative, is a potent 
(lC50=490 nM) inhlbitor of 1-14(C]palmitoyl CoA oxidation in rat heart mitochondria. 
Thus, we sought to determme if CVT-4325 could inhibit FOX and cause a metabolic shift 
in rat isolated hearts. Hearts were perfused for 60 mln in working mode (afterload: 60 
mmHg, preload: 11.5 mmHg, rate: 5Hz) with a modified Krebs solution containing 5.5 
mM 14[C]glucose and 0, 0.4 or 1.2 mM B[H]palmitate bound to 3% BSA. Mechanical 
function was measured throughout perfusion and concentration response curves for the 
effect of CVT-4325 (O-30 PM) on LV work, FOX and GOX were determined. CVT-4325 
had no effect on LV work, cardiac output or coronary flow. CVT-4325 Inhibited FOX in a 
concentration-dependent manner. The IC50 values for inhibition of FOX by CVT-4325 
were 9.7 and 0.9 PM, in the presence of 0.4 and 1.2 mM palmitate, respectively. Inhibi- 
tion of FOX by CVT-4325 was accompanied by an increase in GOX with EC50 values of 
10.9 and 5.6 PM, in the presence of 0.4 and 1.2 mM palmitate, respectively. These data 
indicate that CVT-4325 can induce a metabolic shift in the aerobically perfused heart 
under conditions of stable workload and with a IO-fold greater potency to inhibit FOX with 
higher palmitate levels (1.2 mM). The enhanced potency of CVT-4325 at high fatty acid 
concentrations, such as those associated with myccardial ischemia and cardiac surgery, 
suggests that this new class of FOX inhibitors may possess unique, event-specific car- 
dioprotsctive properties. 
1082-147 Crucial Role of Extracellular Signal-Regulated Kinase 
Pathway in Reactive Oxygen Species-Mediated 
Endothelin-1 Gene Expression Induced by Endothelin-1 
in Rat Cardiac Fibroblasts 
Paul Chan Tzu-Hurng Cheng, Jln-Jer Chen, Taipei Medical University-Wang Fang -3 
Hospital, Taipei, Taiwan,ROC 
Background: Cardiac remodeling is a fundamental response to hypertension, myocardial 
infarction and chronic heart failure. The remodeling involves cardiac fibroblast prolifera- 
bon. Endothelin-1 (ET-l) has been implicated in the fibroblast proliferation. However, the 
mechanism involving ET-l is not clear. The present study was performed to examine the 
role of endogenous ET-l in ET-l-stimulated fibroblast proliferation and the intracellular 
signal transduction pathway of ET-l-induced ET-l gene expression. 
Methods: Rat cardiac fibroblasts were stimulated with ET-l, [3H]thymidine incorporation 
and the ET-l gene expression revealed by Northern blotting and promoter activity assay 
were examined. We also examined the effects of antioxidant pretreatment on ET-I- 
induced proliferation and the redox-sensltlve pathway in cardiac fibroblast. 
Results: ET-l-increased DNA synthesis was inhibited by ET, receptor antagonist 
(BQ485) and endothelin-converting enzyme inhibitor (phosphoramidon). ET-l gene was 
induced by ET-l. ET-l-increased intracellular reactive oxygen species (ROS) was signif- 
icantly inhibited by BQ485 and antioxidants. Antioxidants suppressed ET-l gene expres- 
sion and DNA synthesis stimulated by ET-l. ET-l activated mitogen-activated protein 
kinases (MAPKs) which were significantly inhibited by antioxidants. Only extracellular 
signal-regulated kinase (ERK) inhibitor (UO126) could inhibit ET-l-induced ET-l expres- 
slon. Truncation and mutational analysis of the ET-1 gene promoter showed that activa- 
tor protein-l (AP-I) binding site was an important ciselement in ET-l-induced ET-l 
gene expression. Antioxidants attenuated the ET-l-stimulated AP-1 binding activity. 
Conclusion: Our data suggest that ROS involved in ET-l-induced fibroblast proliferation 
and mediated ET-l-induced activation of ERK pathways, which culminated in ET-l gene 
expression. ET-1 may induce cardiac fibrosis both directly and by the autocrine mecha- 
msm in the heart. 
1082-148 Cardiorenal Actions of the Novel Direct Soluble 
Guanylate Cyclase Stimulator BAY 41-2272 in 
Experimental Congestive Heart Failure In Comparison 
to Nitroglycerin 
Guido Boerriater. Lisa C. Costello-Boerrigter. Harald Lapp, Alessandro Cataliotti, 
Toshihiro Tsuruda, Gail J. Harty, Johannes-Peter Stasch. John C. Burnett, Jr., Mayo 
Clinic and Foundation. Rochester, MN 
Background: Soluble guanylate cyclase (sGC) is a key enzyme in cardiovascular regu- 
latlon as the target of nitric oxide (NO) and the producer of the second messenger cyclic 
guanosine monophosphate. Recently, a novel drug class has been introduced with BAY 
41-2272, an orally available agent that directly stimulates sGC and sensitizes it to NO. 
Unlike conventional nitrate therapy, this effect is not associated with tachyphylaxis. In 
this study we characterized the cardiorenal actions of intravenous BAY 41.2272 !n exper- 
imental congestive heart failure (CHF) and compared it to nitroglycerin (NTG). 
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Methods: CHF was induced in two groups of male mongrel dogs by rapid right ventricu- 
lar pacing at 240 beats per minute for 10 days. In an acute experiment cardiorenal 
parameters were measured in clearances at baseline and with two doses of BAY 41. 
2272 (2 and 10 microgramlkgimin; N=8) and NTG (1 and 5 microgramlkgimln; N=6), 
respectively. Data are expressed as mean * SEM. * indicates a p-value ~0.05. 
Results: BAY 41.2272 reduced mean arterial pressure (from 113*8 to 107*7 and 942.6. 
mmHg), pulmonary artery pressure (from 29+2 to 27+2 and 25*2’ mmHg), pulmonary 
capillary wedge pressure (from 25r2 to 22+2 and 20*2’ mmHg), and increased cardiac 
output (from 2.1*0.2 to 2.2e.03 and 2.3i0.2’ L/mm) and renal blood flow (from 131 +I7 to 
145+18’ and 162+18’ mUmIn). Plasma renin activity, angiotensin II, aldosterone, and 
glomerular filtration rate remamed unchanged. These properties were qualitatively Identi- 
cal to those of NTG. In contrast, whereas NTG reduced right atrial pressure (from 
8.4*1.3 to 7.6kl.3’ and 6.4+1.31 mmHg), it remained unchanged wth BAY 41.2272. Fur- 
thermore, in contrast to NTG, BAY 41-2272 slightly but significantly increased urine flow 
(from 0.10*0.02 to 0.11*0.02 and 0.19iO.04’ mUmin). 
Conclusion: BAY 41-2272 in this experimental model of CHF resulted in beneficial car- 
diac unloading actions. Unlike NTG, it did not reduce right atrial pressure and it acted pri- 
manly as an arterial vasodilator. These characteristics make BAY 41-2272 a promising 
new drug for indications like congestive heart failure, coronary artery disease, and arte- 
rial hypertension. 
inhibition was greater in female cells (~~0.05 compared with males). 
Conclusion: Genistein increases contraction in male, but not female, cardiac myocytes. 
This may be due to a shortened APD and greater block of I ca,L in female myocytes. 
1082-149 Myocardial Protection From Ischemia-Reperfusion by 
TGF-bl via Inhibition of Upregulation of MMP-1 and 
p67phox NADPH Oxidase 
Honaiiana Chen, Dayuan LI, Tom Saldeen, Jawahar L. Mehta, University of Arkansas for 
Medical Sciences, Little Rock, AR, Central Arkansas Veterans Healthcare System, Little 
Rock, AR 
Background: Increasing evidence shows that growth factors, especially transforming 
growth factor-p, (TGF-P,). can protect myocardium from ischemia-reperfusion (I-R) 
injury. Recent studies suggest that matrix metalloproteinases (MMPs) and NADPH OXI- 
dase are involved in myocardial I-R injury. The present study was designed to examme 
the modulation of MMP-1 and NADPH oxidase in the cardioprotective role of TGFQ, dur- 
ing I-R. Materials and Methods: Sprague-Dawley (SD) rats were subjected to 1 hr of 
myocardial &hernia [total left coronary artery (LCA) ligation] followed by 1 hr of reperfu- 
sion (n=9). Parallel groups of rats were pretreated with recombinant TGF-P, (rTGF-P,, 4 
“g/kg. n=9) before reperfusion. or exposed to sham I-R (control group, n=8). After reper- 
fusion, infarct size was determined by Evan bluefIX staining. Besides continuous 
hemodynamic monitoring, MMP-1, p67phox (a subunit of NADPH oxidase), lipid peroxi- 
dation were quantified in I-R myocardial tissues. Results: I-R caused myocardial necro- 
sis and dysfunction indicated by decrease in dp/dt, mean arterial blood pressure and 
heart rate (all PcO.01 vs. sham control group). Simultaneously, expression of MMP-1 and 
p67phox subunit of NADPH oxidase and lipid peroxidation all increased in I-R regions (all 
P<O.Ol vs. sham control group). Importantly, treatment of rats with rTGF-P, reduced the 
extent of myocardlal necrosis and dysfunction despite I-R (all P<O.Ol). rTGF-P, treat- 
ment also inhibited the upregulation of MMP-1 and attenuated lkpid peroxidation and 
p67phox NADPH oxidase expression in the I-R myocardium (all P&05). Conclusion: 
The present study shows that rTGF-P, protects the myocardium from I-R. The effect 
TGF-P, on rep&&ion injury is associated with attenuation of expression of MMP-1 and 
p67phox NADPH oxidase. and lipid peroxidation. 
1082-l 50 Sex Differences in the Response of Cardiac Myocytes to 
the Phytoestrogen, Genistein 
Reoinald Liew, Mark Stagg, Peter Collins, Kenneth T. MacLeod, National Heart and Lung 
Institute, Imperial College, London, United Kingdom 
Background: The soy-phytoestrogen, genistein, appears to be cardioprotective, 
although the relative benefits for man and women are unknown. We tested the hypothe- 
SIS that genistein produces different actions on male and female myocytes. 
Methods: Lefl ventricular myocyte?., isolated from weight-matched male and female 
gumea-pigs, were field stimulated (1 Hz, 37 “C) in a superfusion chamber. Genistein- 
induced changes in cell shortening and the calcium transient were recorded. The effects 
of genisteln on the action potential duration at 50 and 90% repolarization (APD, and 
APD,,, respectively) and the peak L-type calcium current (&) were measured. 
Results: Genisteln increased cell shortenmg in male myocytes at 10 and 4OpM, whilst 
decreasing shortening in female myocytes at 1 pM. 
*p-Q Q5 
Gemstein also increased the calcium transients in male myocytes, but produced little 
effect in female myocytes. 40 phi genistem shortened APD,, in female myocytes from 
329 * 24 ms (mean * SEM) to 245 f 21 ms (n=29, pcO.001) and APD,, from 398 * 25 
ms to 299 * 19 ms (p<O.OOl, n=29), bbt did not significantly affect APD in male myocytes 
(1x22). Furthermore, although 40 &M genistein inhibited ICa,L in both male and female 
myocytes by 47 * 4% (n=23, p&001) and 59 * 3% (ng27, pcO.001) respectively, the 
1082-l 51 Raloxifene Acutely Suppresses Ventricular Myocyte 
Contractility Through Inhibition of the L-Type Calcium 
Current 
Reginald Liew, Mark Stagg. Kenneth T. MacLeod, Peter Collins, National Heart and Lung 
Institute, Imperial College, London, United Kingdom 
Background: The selective estrogen receptor modulator, raloxifene (Ral). is widely used 
in the treatment of postmenopausal osteoporosis. but mav also be cardioorotective. We 
investigated whether it affects myocyte contractility in a similar way to 17P_estradiol. 
Methods: We studied the direct actions of Ral on cell shortenino and the calcium fCa) / 
transient in field-stimulated (1 Hz, 37 “C) left ventricular myocytes isolated from male 
guinea-pigs. The effects of 1 wM Ral were assessed before and after myocyte incubation 
with the specific estrogen receptor antagonist, ICI 182,780 (10 fl) and the nitric oxide 
synthase inhibitor, L-NAME (100pM). Action potential duration (APD) and the L-type Ca 
current (&) were measured using switch-clamptng. 
Results: Ral inhibited cell shortening and the Ca transient in a concentration dependent 
manner. 1 ]IM Ral decreased cell shortening by 33 f 2% (mean * SEM, p<O.OOl. n=l4) 
and the Ca transient by 24 * 2% (p<O.OOl) compared with control values. These Ral- 
induced changes were abolished after incubation with ICI 182,780 (n=ll). whilst incuba- 
tion with L-NAME was without effect (n=l3). 1 FM Ral decreased the time to 90% APD 
repolarisation from 89 * 1% of total APD to 78 * 5% (~~0.05, n=27) and the peak Ica,L by 
59 f 6% (pcO.001, n=8). 
Conclusion: Ral directly suppresses ventricular myocyte contractility at physiologlcal 
concentrations through inhibition of ba,L This appears to be mediated via the estrogen 
receptor and may explain some of the cardioprotective actions of Ral. 
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1083-137 Opposing Effects of Vitamins and Statins on 
Lipoprotein Subclasses in Children With Familial 
Hypercholesterolemia 
Prapti M. Kanani, Dawn C. Thomas, David S. Freedman, Janine E. Janosky, Patricia K. 
Agatisa, Trevor J. Orchard, Children’s Hospital of Pittsburgh, Pittsburgh, PA 
Background: Children with FH merit early therapeutic interventions to prevent premature 
coronary heart disease. We studied the effects of simvastatin and antioxidant vitamms on 
lipid levels and on the lipoprotein subclasses in children with FH. Methods: 10 children (8 
boys, 2 girls) with FH, age 10 to 18 years, have so far completed a double-blind, random- 
ized, cross-over trial with wtamins and statin therapy. Baseline measurements included a 
chemical fasting llpid profile and nuclear magnetic resonance (NMR) spectroscopy to 
study lipoprotein subclasses. Pabents were randomly assigned to 20 mg simvastatin or a 
combination of 400 IU Vitamin E +lOOO mg Vitamin C daily for 12 weeks. Subjects then 
“crossed over” to the other treatment for three months, after which above measurements 
were repeated. A final measurement was performed after withdrawal of all treatment for 
three months. Liooorotein chanaes for both treatments were analvzed bv reoeated mea- , ,. 
sures ANOVA with pcO.05 considered statistically significant. Results: At baseline, chem- 
lcallv measured mean total cholesterol fTCl was 250 maldl. LDL 186 moldl. HDL 35 and 
triglycerides (TG)l46mg/dl. After statin therapy, mean TC decreased by 27% (p= O.Ol), 
LDL 34% (p=O.Ol), TG 27% (p=O.O3) while HDL Increased 8% (p=O.39). NMR measure- 
ments showed an increase in HDL particle size (p=O.Ol), decrease in LDL particle con- 
centration (p=O.OOl) and a trend towards increase in LDL particle size. In contrast, after 
vitamins, there was negligible change from baseline in chemically measured TC (O%), 
LDL(-3%), some change in HDL (+5%). wth a trend towards increase in TG (34%). NMR 
showed a significant decrease in LDL (p=O.b2) and HDL size (p=O.Ol) and a decrease in 
the amount of large HDL (p=O.O3). Conclusions: In our study, vitamins lowered the 
amount of protective large HDL, and decreased both HDL and LDL size, increasing 
atherogenic lipoproteins. In contrast, simvastatin therapy raised HDL size in addition to 
lowering LDL partlcle concentration. These results in children with FH support the fmd- 
ings from the HATS study that anttoxidant vitamin therapy may adversely affect lipopro- 
tern distribution. 
